Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

MoxiMed

26460 Corporate Ave, Suite 100
Hayward, CA 94545
USA
510.887.3300
Website Company Summary Management Team
Management

CEO: Kevin Sidow (2/29/2008)
General Management: Vicki Hacker (6/30/2008); Luigi Bivi (1/2011) ; Thomas Michal (9/30/2008)
Finance: Daniel Murray (11/30/2016)
Technology: Anton Clifford (2006)
Sales/Marketing: Keith Fong
Board

Outside board: (May no longer be on the board) Michael A. Bates (MoxiMed Former Consulting CFO) Robert K. Anderson (Valleylab Former CEO/Chairman) Ryan D. Drant (NEA General Partner) John Nehra (NEA General Partner) Hank A. Plain (Morgenthaler Ventures) Joshua Makower (NEA Venture Partner) Robert More (Frazier Healthcare Partners General Partner) Robert W. Croce (Johnson & Johnson Former Company Group Chairman) Arthur Franken (Gilde Healthcare Partners Partner) Christopher Shen (Vertex Ventures Managing Director)
Company

Business description: Osteoarthritis (OA), the most common form of arthritis, affects an estimated 35 - 40 million Europeans.1 Also known as degenerative joint disease, OA leads to a breakdown of a joint's cartilage and often results in joint pain and loss of motion. OA commonly affects the knees, hips, hands, or back. The goals of OA treatment include minimizing joint pain, restoring normal activity levels, and slowing disease progression. However, many current therapies are either ineffective or involve highly invasive, joint modifying procedures. Moximed is initially focused on developing minimally invasive, joint sparing solutions for patients with knee osteoarthritis. Researchers recognize that excessive forces acting on a joint contribute to the onset and progression of OA.2, 3 In response, Moximed created The KineSpring® Knee Implant System, a revolutionary new device designed to absorb excess weight that is normally supported by the knee joint. The KineSpring System has been evaluated by leading surgeons in multiple, international clinical studies. It has been granted CE Mark and is currently available for sale in select centers in Europe and Australia.
Capital

Rounds: 5
Recent Fundings: Mar 2017   Jan 2016
Capital raised: 143.2M
Last Round: 50.0M
Ownership: Private  

Last Tweets


 

Last Mentions


Overview
Record updated: Mar 2017
Sector: Medical
Year Founded: 2009
Rounds: 5
Recent Fundings: Mar 2017   Jan 2016
Capital Raised: 143.2M
Last Round: 50.0M
Ownership: Private